Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis
- Authors:
- Published online on: April 1, 2010 https://doi.org/10.3892/ijmm_00000385
- Pages: 625-633
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
HE3286 (17α-ethynyl-5-androstene-3β, 7β, 17β-triol) is an orally bio-available synthetic derivative of naturally occurring androstene-3β, 7β, 17β-triol. Our present data show that oral treatment with HE3286, favourably influenced the course of arthritis in the rat model of adjuvant-induced arthritis (reduced cumulative disease scores and paw edema), and in the mouse model of collagen antibody-induced arthritis (reduced clinical paw scores). Importantly, HE3286 was not immune suppressive in human mixed lymphocyte reaction or in animals challenged with Coxsackie B3 virus. HE3286 is currently in phase I/II clinical trials in rheumatoid arthritis and ulcerative colitis and these findings further strengthen the possibility that HE3286 may represent an effective anti-inflammatory agent useful for treating chronic inflammation with a more attractive safety profile than glucocorticoids or cyclooxygenase inhibitors.
